NYSE$HIMS
Hims & Hers Health Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Revenue increased and the company invested in infrastructure and technologies.
Hims & Hers Health, Inc. reported a 69% year-over-year increase in revenue to $60.7 million for Q2 2021. The company is focused on building a unified consumer platform across multiple medical specialties.
- Revenue was $60.7 million for the second quarter 2021 compared to $35.9 million for the second quarter 2020, an increase of 69% year-over-year.
- Net loss was $(9.2) million for the second quarter 2021 compared to $(1.0) million for the second quarter 2020.
- Gross margin was 78% for the second quarter 2021 compared to 71% for the second quarter 2020.
- Adjusted EBITDA was $(4.7) million for the second quarter 2021 compared to $1.2 million for the second quarter 2020.
Headline financials
Revenue & EPS history
Hims & Hers · Revenue · Quarterly
$60.7M
Revenue by segment
Hims & Hers · $60.7M total across 2 segments · Q2 2021
- Online Revenue$58.1M+74.7%95.8%
- Wholesale Revenue$2.55M-2.8%4.2%
Forward guidance
For the third quarter 2021, Hims & Hers expects revenue to be in the range of $69 million to $71 million and Adjusted EBITDA to be in the range of $(9) million to $(11) million. For the full year 2021, the company expects revenue to be in the range of $251 million to $255 million and Adjusted EBITDA to be in the range of $(35) million to $(40) million.
Tailwinds
- Revenue to be in the range of $69 million to $71 million for Q3 2021.
- Adjusted EBITDA to be in the range of $(9) million to $(11) million for Q3 2021.
- Revenue to be in the range of $251 million to $255 million for the full year 2021.
- Adjusted EBITDA to be in the range of $(35) million to $(40) million for the full year 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
+2.5%
Avg return
Earnings day
+3.8%
Avg return
5 days after
+11.7%
Avg return
30 days after
50%
13 / 26 earnings
Positive
+41.1%
Q4 2023
Best reaction
-22.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.0% | -11.4% | -1.8% | |
| Q4 2025 | -2.8% | -6.4% | +34.5% | |
| Q3 2025 | -3.6% | -7.6% | -9.8% | |
| Q1 2025 | +18.5% | +24.1% | +26.0% | |
| Q4 2024 | -22.3% | -12.1% | -37.8% | |
| Q3 2024 | +1.4% | +15.0% | +66.6% | |
| Q2 2024 | -4.0% | -9.2% | -16.9% | |
| Q1 2024 | +9.7% | +9.1% | +93.2% | |
| Q4 2023 | +41.1% | +37.8% | +65.3% | |
| Q3 2023 | +7.6% | +5.1% | +37.3% | |
| Q2 2023 | -8.7% | -11.7% | -15.2% | |
| Q1 2023 | -11.5% | -10.2% | -23.9% | |
| Q4 2022 | +15.4% | +6.0% | +2.7% | |
| Q3 2022 | +30.1% | +37.2% | +64.7% | |
| Q2 2022 | -3.4% | +9.2% | -0.6% | |
| Q1 2022 | -13.0% | -13.5% | +5.3% | |
| Q4 2021 | +8.0% | +20.5% | +19.8% | |
| Q3 2021 | -7.0% | -1.3% | -26.3% | |
| Q2 2021 | +7.0% | -4.7% | +11.1% | |
| Q1 2021 | +13.7% | +44.9% | +33.1% | |
| Q2 2020 | -8.4% | -7.2% | -21.9% | |
| Q4 2020 | -7.5% | -15.4% | -21.3% | |
| Q3 2020 | +0.1% | +0.0% | +17.5% | |
| Q1 2020 | -0.7% | -0.5% | +0.1% | |
| Q4 2019 | +1.4% | +2.1% | +2.2% | |
| Q3 2019 | +0.0% | +0.3% | -0.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro